Vesper Biotech Raises R$25 Million for Innovation

Vesper, a venture builder dedicated to advancing biotechnology, has successfully closed an initial funding round of R$ 25 million. This capital infusion was primarily supported by members of the influential Lafer family, associated with the prominent Klabin conglomerate, alongside venture capital firms Rise Venture and ACNext. The company aims to secure an additional R$ 50 million by the close of the year, signaling ambitious growth plans in the burgeoning biotech sector.

With a current portfolio comprising eight innovative startups, holding 17 international patents, Vesper has already attracted significant backing, accumulating over R$ 200 million from private investors and federal innovation programs like Finep and Embrapii. Founded in 2018, Vesper typically retains a substantial equity stake, between 30% and 35%, in its health and agriculture-focused biotech ventures. The firm plays an active role in managing these companies, often stepping in to formalize and develop promising research that originates from academic institutions, even before the startups possess a formal corporate structure.

Gabriel Bottós, founder and CEO of Vesper, highlighted the critical need for Vesper's model in Brazil, noting a gap in entrepreneurial culture among scientists. "Our mission is to identify, vet, and cultivate ideas into companies alongside scientists, building upon decades of university research," Bottós explained. This latest funding round sees the investors becoming equity partners in Vesper itself, with the founding team retaining an 80% stake in the holding company. Investors also retain the option to directly fund startups during their subsequent capital-raising efforts, with Vesper coordinating these processes.

The newly acquired capital will be strategically deployed to advance crucial validation stages for the agricultural technology startups and to support clinical trials for the human health ventures. This phase is designed to generate robust data, positioning Vesper and its portfolio companies for engagement with major global biotechnology venture capital firms. "We are preparing our portfolio to compete at the highest level," Bottós stated, emphasizing the goal of attracting international expertise and strategic partnerships through demonstrated success in advanced clinical studies and field trials.

Vesper's strategic focus on radical innovation, particularly in genetic engineering, aims to "reprogram cells" rather than just code computers. This passion was ignited by a personal experience involving a family member's successful treatment for neuroblastoma, underscoring the transformative potential of biotech. Among its promising ventures, Vyro, co-founded by renowned geneticist Mayana Zatz, is exploring the use of the Zika virus to target brain tumors. Concurrently, Aptah Bio is developing mRNA-based therapies for neurodegenerative diseases like Alzheimer's and aggressive brain cancers, having demonstrated promising results in preclinical studies that suggest neuronal rejuvenation.

Further bolstering its credibility, Aptah Bio recently secured Orphan Drug Designation (ODD) from the FDA for one of its investigational drugs. This designation is a significant catalyst, potentially accelerating clinical development and attracting specialized investors who focus on therapies for rare diseases. In the agricultural domain, Symbiomics is making strides with its AI-driven approach to developing novel biological fertilizers, aiming to significantly reduce reliance on chemical inputs. This innovative methodology differentiates it from many "me-too" technologies prevalent in the biologicals market, as evidenced by a previous Series A round led by Corteva.

The Lafer family's investment, managed by Tiago Lafer, reflects confidence in Vesper's dual-pronged approach, which balances the risk mitigation offered by agricultural innovations with the high-multiple potential of medical science breakthroughs. Vesper's operational model, which includes establishing companies in Delaware with operational hubs in Brazil and providing infrastructure like its Florianópolis innovation center, is designed to nurture promising research from lab to market, potentially establishing Brazil as a key player in the global biotechnology arena.